Business
Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by
About this update from Pulse Biosciences, Inc
[{"type":"text","content":" HAYWARD, Calif.--(BUSINESS WIRE)--\nPulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced preliminary unaudited fourth quarter 2021 financial and operational results.\n\nRecent Highlights:\n\n\nPreliminary unaudited full year 2021 revenue is expected to be in the range of $1.3 million to $1.4 million, including preliminary unaudited fourth quarter 2021 revenue of approximately $750 thousand\n\n\nCompleted the first two commercial sales of CellFX Systems in the fourth quarter of 2021\n\n\nTransitioned 17 Controlled Launch Program participants to commercial use of their acquired CellFX System, bringing the total number of commercial conversions to 29 at the end of the fourth quarter of 2021\n\n\nCompleted onboarding CellFX Controlled Launch Program participants, increasing the total number of program participants to 70. Six clinics have opted out of the program to date.\n\n\n“We are proud of our accomplishments in 2021,” said Darrin Uecker, President and CEO of Pulse Biosciences. “We achieved regulatory approval for the CellFX System in the U.S., Europe and Canada, onboarded Controlled Launch Program participants, expanded commercialization across each geography and continued to advance our clinical and regulatory initiatives. These achievements position Pulse Biosciences to drive meaningful growth in 2022 and beyond as we leverage the full potential of NPS technology in dermatology and other medical specialties.”\n\nThe Company’s fourth quarter 2021 financial results are preliminary and are subject to the completion of the Company’s 2021 audit. Complete fourth quarter and full year 2021 financial results will be announced in March.\n\nAbout Pulse Biosciences®\n\nPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commerc...